Literature DB >> 16647342

Glutathione depletion of stimulator cells inhibits responder T-cell immunogenicity in vitro and prolongs allograft survival in vivo.

Gregory J McKenna1, Peter T W Kim, Alice L F Mui, Christopher J Ong, Ori D Rotstein, Garth L Warnock, Stephen W Chung.   

Abstract

BACKGROUND: Pretransplant donor-organ immunomodulation may attenuate allograft rejection by changing the redox state of donor cells. This study explored impact of donor-cell redox-state alteration by glutathione (GSH) depletion on graft immunogenicity.
METHODS: Splenic and heart endothelial cells from Balb/c mice were treated with diethylmaleate (a GSH-depleting agent) and/or lipopolysaccharide to assess the impact of GSH depletion on alloreactivity by mixed lymphocyte reaction, endothelial cell adhesion by T-cell adhesion assay, intracellular adhesion molecule-1 expression by reverse transcriptionase-polymerase chain reaction, and nuclear factor-kappa B upregulation by electrophoretic mobility shift assay. Heterotopic heart transplants were performed as in vivo correlate.
RESULTS: GSH depletion decreased endothelial cell and splenic cell alloreactivity, decreased endothelial cell intracellular adhesion molecule-1 expression through attenuation of nuclear factor-kappa B activity, decreased endothelial cell adhesion, and prolonged heterotopic heart transplant graft survival.
CONCLUSIONS: GSH depletion may represent a significant immunomodulator of donor antigenicity to prevent transplant rejection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647342     DOI: 10.1016/j.amjsurg.2006.02.006

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Strategic faculty recruitment increases research productivity within an academic university division.

Authors:  Stephen W Chung; Joanne S Clifton; Andrea J Rowe; Richard J Finley; Garth L Warnock
Journal:  Can J Surg       Date:  2009-10       Impact factor: 2.089

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.